Dystrogen 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DEC / Dystrogen
2022-003126-42: Clinical Trial (Phase 1/2 ) to Evaluate the Safety and Efficacy of DT-DEC01 Therapy in Patients with Duchenne Muscular Dystrophy Badanie kliniczne fazy 1/2 oceniające bezpieczeństwo i skuteczność terapii DT-DEC01 u pacjentów z dystrofią mięśniową Duchenne’a

Not yet recruiting
1/2
20
Europe
DT-DEC01 (MB^N/MB^DMD DEC), DT-DEC01, Suspension for injection
Dystrogen Therapeutics Technology Polska Spółka z Ograniczoną Odpowiedzialnością, Dystrogen Therapeutics Technology Polska Spółka z Ograniczoną Odpowiedzialnością
Duchenne muscular dystrophy (DMD) is the most common inherited neuromuscular disease that mostly affects boys. DMD is a type of X-linked disease caused by a mutation of the gene at the Xp21 locus that encodes the dystrophin protein, resulting in a complete lack of this protein in the muscles of affected boys. DMD is characterized by skeletal and cardiac muscle degeneration. Most DMD-affected boys lose their ability to walk by the age of 10-14., Duchenne muscular dystrophy (DMD) is the most common inherited neuromuscular disease that mostly affects boys. DMD is characterized by skeletal and cardiac muscle degeneration., Diseases [C] - Musculoskeletal Diseases [C05]
 
 
Trimera / Dystrogen
No trials found
DT-202 / Dystrogen
No trials found

Download Options